Genome Editing/Genome Engineering Market Demand, Size, Trends and Forecast 2030

Genome Editing/Genome Engineering Market Size, Share & Trends Analysis By Product & Service, By Application, By Technology, By End-Users, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Published: Feb-2022	Report ID: BIOT2201	Pages: 1 - 265	Formats^*:
Category : Biotechnology

Global Genome Editing & Genome Engineering Market Overview:

According to SPER Market Research, the Genome Editing and Genome Engineering Market is estimated to reach USD 25.3 billion by 2030 with a CAGR of 19.5%. Academies & government research centre used genome engineering before, now it is diversified into clinical & diagnostic fields too, this leads to the escalation of the market.

Impact of COVID-19 on the Genome Editing/Genome Engineering Market

The outbreak of COVID-19 has boosted the investment of pharmaceutical companies and biopharmaceutical companies, and genomic market player in research & development and in vaccine.

Scope of the report:

Report Metric	Details
Market size available for years	2019-2030
Base year considered	2021
Forecast period	2022-2030
Segments covered	By Product & Service, By Application, By Technology, By End Users, By Region
Geographies covered	North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered	Agilent Technologies, Beam Therapeutics, Bluebird Bio, Caribou Biosciences., Cellectis S.A, Creative Biogene, CRISPR Therapeutics AG, Editas Medicine, GenScript, Integrated DNA Technologies, Intellia Therapeutics, Lonza, Merck KGaA, New England Biolabs, OriGene Technologies, PerkinElmer, Precision Biosciences, Recombinetics, Regeneron Pharmaceuticals, Sangamo Therapeutics, Synthego, Tecan Life Sciences, Thermo Fisher Scientific, Transposagen, Biopharmaceuticals, Vigene Biosciences

Driver: Increase in funding

In the recent years there is increase in the government funding globally in the genomic research this allows academies & research centre to work on genomic engineering.

Restraints: Off-target effect of CRISPR Technology

CRISPR-Cas9 has an Off-target effects, The mismatch tolerance capacity of CRISPR-Cas9 is one to three, beyond this leads to off-target nuclease activity; it can be the reason for mutations in these genes in turn oncogenesis.

Opportunity: widespread use of Genome Engineering

Due to better efficacy, compliance, economical, optimization of therapy the demand for personalized medicine increasing worldwide. Personalized medicine markets offering lots of opportunities to the genomic market.

Challenges: Costly equipment

At the beginning, this might be costly for the academic research to afford, but in later stage the advanced technology is going to build affordable instruments, so it is a short term challenges for this market.

Global Genome Editing/Genome Engineering Market, by Product & Service: Based on the Product & Service, Global Genome Editing/Genome Engineering Market is segmented as; Reagents & consumables, Services, Software & systems

Global Genome Editing/Genome Engineering Market Segmentation:

By Application: Based on the Application, Global Genome Editing/Genome Engineering Market is segmented as; Cell Line Engineering, Diagnostic applications, Drug discovery & development, Genetic Engineering, Other applications

By Technology: Based on the Technology, Global Genome Editing/Genome Engineering Market is segmented as; Antisense, CRISPR, TALEN, ZFN, Other technologies.

By End-Users: Based on the End-Users, Global Genome Editing/Genome Engineering Market is segmented as; Academic & Government Research Institutes, Biotechnology companies, Pharmaceutical companies.

By Region: North America owns the prime share of this market; it is because of growing exploitation of genetically modified crops, gene therapy, government grants and funding.

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Dynamics

4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges

4.3. COVID-19 Impact on the Genome Editing/Genome Engineering Market
4.4. Market Trends

5. Global Genome Editing/Genome Engineering Market, by Product & Service, 2019-2030 (USD Million)

5.1. Reagents & consumables
5.2. Services
5.3. Software & systems

6. Global Genome Editing/Genome Engineering Market, by Application, 2019-2030 (USD Million)

6.1. Cell Line Engineering
6.2. Diagnostic applications
6.3. Drug discovery & development
6.4. Genetic Engineering
6.5. Other applications

7. Global Genome Editing/Genome Engineering Market, by Technology, 2019-2030 (USD Million)

7.1. Antisense
7.2. CRISPR
7.3. TALEN
7.4. ZFN
7.5. Other technologies

8. Global Genome Editing/Genome Engineering Market, by End-Users, 2019-2030 (USD Million)

8.1. Academic & Government Research Institutes
8.2. Biotechnology companies
8.3. Pharmaceutical companies

9. Global Genome Editing/Genome Engineering Market, by Region, 2019-2030 (USD Million)

9.1. North America

9.1.1. US
9.1.2. Canada

9.2. Europe

9.2.1. France
9.2.2. Germany
9.2.3. Italy
9.2.4. Spain
9.2.5. UK
9.2.6. Rest of the Europe

9.3. Asia Pacific

9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Rest of Asia Pacific

9.4. Latin America
9.5. Middle East
9.6. Africa

10. Competitive Landscape

10.1. Introduction
10.2. Market Share Analysis, By Key Players
10.3. Competitive Scenario
10.3.1. Product Launches
10.3.2. Partnerships, Collaborations and Agreements
10.3.3. Acquisitions
10.3.4. Expansions
10.3.5. Other Developments

11. Company Profiles

11.1. Agilent Technologies
11.2. Beam Therapeutics
11.3. Bluebird Bio
11.4. Caribou Biosciences.
11.5. Cellectis S.A
11.6. Creative Biogene
11.7. CRISPR Therapeutics AG
11.8. Editas Medicine
11.9. GenScript
11.10. Integrated DNA Technologies
11.11. Intellia Therapeutics
11.12. Lonza
11.13. Merck KGaA
11.14. New England Biolabs
11.15. OriGene Technologies
11.16. PerkinElmer
11.17. Precision Biosciences
11.18. Recombinetics
11.19. Regeneron Pharmaceuticals
11.20. Sangamo Therapeutics
11.21. Synthego
11.22. Tecan Life Sciences
11.23. Thermo Fisher Scientific
11.24. Transposagen Biopharmaceuticals
11.25. Vigene Biosciences

12. Appendix

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1